Janus Henderson Group PLC Trims Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Janus Henderson Group PLC trimmed its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 27.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 635,347 shares of the biotechnology company’s stock after selling 234,772 shares during the quarter. Janus Henderson Group PLC’s holdings in United Therapeutics were worth $145,950,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Dimensional Fund Advisors LP boosted its stake in United Therapeutics by 1.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 561,950 shares of the biotechnology company’s stock worth $123,566,000 after purchasing an additional 9,962 shares in the last quarter. LSV Asset Management lifted its stake in shares of United Therapeutics by 40.3% in the first quarter. LSV Asset Management now owns 529,519 shares of the biotechnology company’s stock worth $121,641,000 after buying an additional 152,151 shares in the last quarter. Norges Bank purchased a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $100,519,000. Charles Schwab Investment Management Inc. increased its position in shares of United Therapeutics by 2.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 319,030 shares of the biotechnology company’s stock valued at $70,152,000 after acquiring an additional 7,723 shares in the last quarter. Finally, Nordea Investment Management AB raised its holdings in United Therapeutics by 677.6% in the 1st quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock worth $72,422,000 after acquiring an additional 262,222 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Trading Down 4.8 %

Shares of UTHR stock traded down $16.19 during trading hours on Wednesday, reaching $321.35. 224,340 shares of the stock were exchanged, compared to its average volume of 489,569. The firm has a market capitalization of $14.26 billion, a price-to-earnings ratio of 15.96, a price-to-earnings-growth ratio of 1.08 and a beta of 0.55. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $343.98. The company’s 50-day moving average price is $305.47 and its 200-day moving average price is $259.37. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.63 by $0.54. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The business had revenue of $677.70 million during the quarter, compared to analyst estimates of $620.31 million. During the same quarter in the previous year, the business earned $4.86 earnings per share. The company’s revenue for the quarter was up 33.7% compared to the same quarter last year. As a group, equities analysts anticipate that United Therapeutics Co. will post 25.59 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on UTHR. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Monday, July 15th. Morgan Stanley cut United Therapeutics from an “overweight” rating to an “equal weight” rating and raised their target price for the stock from $310.00 to $321.00 in a research report on Thursday, July 11th. TD Cowen upped their price target on shares of United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. HC Wainwright boosted their target price on shares of United Therapeutics from $300.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Finally, Wells Fargo & Company increased their price target on shares of United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 12th. Two analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $330.64.

Insider Buying and Selling

In other United Therapeutics news, Director Christopher Causey sold 2,240 shares of the company’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $259.91, for a total value of $582,198.40. Following the transaction, the director now owns 4,185 shares of the company’s stock, valued at approximately $1,087,723.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Christopher Causey sold 2,240 shares of the company’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $259.91, for a total value of $582,198.40. Following the transaction, the director now directly owns 4,185 shares in the company, valued at $1,087,723.35. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Nilda Mesa sold 266 shares of United Therapeutics stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $318.58, for a total transaction of $84,742.28. Following the sale, the director now owns 5,107 shares of the company’s stock, valued at approximately $1,626,988.06. The disclosure for this sale can be found here. In the last three months, insiders sold 100,884 shares of company stock valued at $29,994,539. Insiders own 12.50% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.